For Booming Biotech Firms, a New Threat: Generics
March 14, 2007 | Inside, scientists at U.S. generics maker Barr Pharmaceuticals Inc. are working on copycat versions of some of biotech's biggest hits, drugs that cost the American health-care system billions of dollars a year. Their goal is to sell them someday in the U.S. Story in The Wall Street Journal (sub. req.)
Feeds